MCID: ANS025
MIFTS: 40

Anus Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Anus Benign Neoplasm

MalaCards integrated aliases for Anus Benign Neoplasm:

Name: Anus Benign Neoplasm 12 15
Anal Neoplasm 12 17
Neoplasm of Anus 12
Anus Neoplasms 45
Anal Tumors 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4551
MeSH 45 D001005
NCIt 51 C2877
UMLS 74 C0003463

Summaries for Anus Benign Neoplasm

MalaCards based summary : Anus Benign Neoplasm, also known as anal neoplasm, is related to anal canal carcinoma and anal canal squamous cell carcinoma. An important gene associated with Anus Benign Neoplasm is SETD1A (SET Domain Containing 1A, Histone Lysine Methyltransferase), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Oxaliplatin and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lung, and related phenotypes are growth/size/body region and digestive/alimentary

Related Diseases for Anus Benign Neoplasm

Diseases related to Anus Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 anal canal carcinoma 30.4 CDKN2A KRT7
2 anal canal squamous cell carcinoma 30.3 CDKN2A KRT5 SERPINB3
3 anus cancer 30.2 CDKN2A CDX2 IARS KRT5 KRT7 RORC
4 anal canal adenocarcinoma 30.0 CDX2 KRAS KRT7
5 anus sarcoma 11.1
6 histiocytic sarcoma 10.3 BRAF CDKN2A
7 bladder squamous cell carcinoma 10.3 BRAF CDKN2A
8 spitz nevus 10.3 BRAF CDKN2A
9 acral lentiginous melanoma 10.3 BRAF CDKN2A
10 vulva squamous cell carcinoma 10.3 CDKN2A SERPINB3
11 optic nerve sheath meningioma 10.2 CDKN2A KRT5
12 papillary craniopharyngioma 10.2 BRAF KRT7
13 keratinizing squamous cell carcinoma 10.2 CDKN2A KRT5
14 lymphoepithelioma-like thymic carcinoma 10.2 CDKN2A KRT5
15 ovary neuroendocrine neoplasm 10.2 CDX2 KRT7
16 appendix adenocarcinoma 10.2 CDX2 KRT7
17 urachal adenocarcinoma 10.2 BRAF KRAS
18 mucinous adenofibroma 10.2 CDX2 KRT7
19 anus adenocarcinoma 10.2 CDX2 KRT7
20 metanephric adenoma 10.2 BRAF KRT7
21 hyperplastic polyposis syndrome 10.2 BRAF KRAS
22 glandular cystitis 10.2 CDX2 KRT7
23 vulval paget's disease 10.2 CDKN2A KRT7
24 adenoid basal cell carcinoma 10.2 CDKN2A KRT7
25 bile duct adenoma 10.2 CDKN2A KRT7
26 endocervical carcinoma 10.2 CDKN2A KRT7
27 bladder carcinoma in situ 10.2 CDKN2A KRT7
28 balloon cell malignant melanoma 10.2 KRT5 KRT7
29 benign breast adenomyoepithelioma 10.2 KRT5 KRT7
30 breast adenomyoepithelioma 10.2 KRT5 KRT7
31 ceruminoma 10.2 KRT5 KRT7
32 epithelial predominant wilms' tumor 10.2 CDX2 KRT7
33 malignant spiradenoma 10.2 KRT5 KRT7
34 benign mesothelioma 10.2 KRT5 KRT7
35 ovarian mucinous adenocarcinoma 10.2 CDX2 KRT7
36 sensory organ benign neoplasm 10.2 KRT5 KRT7
37 thymus adenocarcinoma 10.2 CDX2 KRT7
38 bile duct mucoepidermoid carcinoma 10.2 KRT5 KRT7
39 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A KRT7
40 middle ear adenoma 10.2 KRT5 KRT7
41 gastric diffuse adenocarcinoma 10.2 CDX2 KRT7
42 large cell acanthoma 10.1 KRT5 KRT7
43 bladder adenocarcinoma 10.1 CDX2 KRT7
44 chronic cystitis 10.1 CDX2 KRT7
45 apocrine sweat gland neoplasm 10.1 KRT5 KRT7
46 mature teratoma 10.1 BRAF KRAS
47 colonic benign neoplasm 10.1 BRAF KRAS
48 rectum adenocarcinoma 10.1 CDX2 KRT7
49 mucinous ovarian cystadenoma 10.1 CDX2 KRT7
50 malignant biphasic mesothelioma 10.1 KRT5 KRT7

Graphical network of the top 20 diseases related to Anus Benign Neoplasm:



Diseases related to Anus Benign Neoplasm

Symptoms & Phenotypes for Anus Benign Neoplasm

MGI Mouse Phenotypes related to Anus Benign Neoplasm:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.91 BRAF CCND1 CDKN2A CDX2 H2AFY2 KRAS
2 digestive/alimentary MP:0005381 9.87 BRAF CCND1 CDKN2A CDX2 KRAS KRT5
3 neoplasm MP:0002006 9.55 BRAF CCND1 CDKN2A CDX2 KRAS
4 pigmentation MP:0001186 9.26 BRAF CDKN2A H2AFY2 KRAS
5 reproductive system MP:0005389 9.17 BRAF CCND1 CDKN2A CDX2 H2AFY2 KRAS

Drugs & Therapeutics for Anus Benign Neoplasm

Drugs for Anus Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Antibodies Phase 4,Phase 2,Phase 1
4 Immunoglobulins Phase 4,Phase 2,Phase 1
5 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Pharmaceutical Solutions Phase 4,Not Applicable
9
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
12
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
14
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
15
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
16 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
20 Anesthetics Phase 3,Phase 1,Not Applicable
21 interferons Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
27 Mitomycins Phase 3,Phase 2,Phase 1,Early Phase 1
28 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antineoplastic Agents, Hormonal Phase 3
31 Gastrointestinal Agents Phase 3,Phase 2
32 Narcotics Phase 3
33 Adjuvants, Anesthesia Phase 3
34 Analgesics Phase 3,Phase 2
35 Anesthetics, Intravenous Phase 3
36 Anesthetics, General Phase 3
37 Analgesics, Opioid Phase 3
38 Central Nervous System Depressants Phase 3,Phase 2
39 Peripheral Nervous System Agents Phase 3,Phase 2
40 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
41 Interferon Inducers Phase 3
42
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
43
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
47
Cidofovir Approved Phase 2 113852-37-2 60613
48
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
49
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
50
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 21704 32326

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
4 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
5 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
6 Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
7 Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
8 Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Completed NCT01164722 Phase 3
9 An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) Completed NCT00090285 Phase 3
10 Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) Completed NCT01651949 Phase 3
11 Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
12 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed NCT01461096 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
15 Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
16 Immunogenicity From 1 Dose of Bivalent HPV Vaccine in Girls to 3 Doses of Quadrivalent Vaccine in Women: the PRIMAVERA-ESCUDDO Trial Recruiting NCT03728881 Phase 3
17 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
18 Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
19 Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
20 Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
21 International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
22 A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Unknown status NCT00754078 Phase 2
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Completed NCT00324415 Phase 2 cisplatin;fluorouracil
25 SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Completed NCT00052897 Phase 1, Phase 2
26 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
27 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
28 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Completed NCT00550589 Phase 2 cidofovir
29 Vectibix for the Treatment of Anal Cancer Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
30 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
31 Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men Completed NCT00428285 Phase 2
32 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
33 Erlotinib in Treating Patients With Advanced Kidney Cancer Completed NCT00045487 Phase 2 OSI-774
34 A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
35 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
36 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
37 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
38 Oral Rigosertib for Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
39 Pembrolizumab in Refractory Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
40 Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
41 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
42 Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Recruiting NCT03381352 Phase 2 Capecitabine;Mitomycin C
43 A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
44 Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) Recruiting NCT03944252 Phase 2 Avelumab;Cetuximab
45 Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Recruiting NCT03233711 Phase 2
46 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Recruiting NCT03499795 Phase 2
47 Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
48 LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
49 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
50 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C

Search NIH Clinical Center for Anus Benign Neoplasm

Cochrane evidence based reviews: anus neoplasms

Genetic Tests for Anus Benign Neoplasm

Anatomical Context for Anus Benign Neoplasm

MalaCards organs/tissues related to Anus Benign Neoplasm:

42
Breast, Testes, Lung, Lymph Node, Bone, Prostate, Appendix

Publications for Anus Benign Neoplasm

Articles related to Anus Benign Neoplasm:

# Title Authors Year
1
Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm. ( 26658220 )
2016

Variations for Anus Benign Neoplasm

Expression for Anus Benign Neoplasm

Search GEO for disease gene expression data for Anus Benign Neoplasm.

Pathways for Anus Benign Neoplasm

GO Terms for Anus Benign Neoplasm

Cellular components related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 BRAF CCND1 CDKN2A CDX2 H2AFY2 KRT5

Biological processes related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to corticosterone GO:0051412 8.96 CCND1 PEBP1
2 positive regulation of cellular senescence GO:2000774 8.62 CDKN2A KRAS

Molecular functions related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 8.92 BRAF IARS KRAS PEBP1

Sources for Anus Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....